Recent Updates
Recently added Catalysts
SRTS Positive Sentiment

Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sensus Healthcare, a medical device company, will announce its financial results for Q2 2026 on August 13, 2026. The company will hold a conference call at 4:30 PM ET to discuss the results and provide a business update. This event will also include a Q&A session for participants.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sensus Healthcare is committed to effective treatments.
  • The upcoming conference call will provide valuable updates.
  • Management is engaging with stakeholders through Q&A.

Full Press Release Details

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc

Frequently Asked Questions

When will Sensus Healthcare report its Q2 2026 results?

Sensus Healthcare will report its Q2 2026 financial results on August 13, 2026.

What time is the conference call for the Q2 results?

The conference call will begin at 4:30 PM Eastern time.

What will be discussed during the conference call?

The call will review financial results and provide a business update.

Will there be a Q&A session during the call?

Yes, there will be a Q&A session for participants.

ShareAdd on Google
Tags: SRTS Viatris Investor Conferences Healthcare Sensus Healthcare financial results conference call business update
Last updated: Jul 30, 2026

Biotech snapshot

Cash runway
$18M liquidity · $1M/mo burn
~12 mo
Low dilution risk